Dr. Raúl Insa, SOM Biotech CEO, gave a talk on the topic “Repositioning of Utrophin” at the International Congress 2019 on Duchenne Muscular Dystrophy and Becker, an event organized by Duchenne Parent Project España. The Congress took place in Madrid from 7th to 9th of June.
The Congress analyzed the different therapeutic strategies that exist today, in addition to the key challenges and priorities to improve the quality of life of children, adolescents, and adults with Duchenne Muscular Dystrophy and Becker. A panel of national and international experts provided their knowledge on current treatments which are under research. In addition, families and patients had the opportunity to learn the latest advances in the fight against these diseases.
SOM Biotech is carrying out the project entitled “Repositioning of Drugs to treat Duchenne Muscular Dystrophy (DMD)” at the framework of the collaboration with Duchenne Parent Project España. The compound SOM2201, included in the early stage pipeline of SOM Biotech, is currently at in vitro validation stage.
You can find more information about the Congress, and Duchenne Parent Project España here: https://www.duchenne-spain.org.